Back to News
Market Impact: 0.35
Amneal Pharma Posts Wider Q3 Loss Despite 10% Revenue Growth; Raises FY26 Outlook
Source: Nasdaq
Corporate EarningsCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Amneal Pharmaceuticals reported 10% revenue growth in the third quarter ended September 30, 2026, but its loss widened. The company raised its full-year 2026 guidance; the article provides no figures for the loss or revised outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
AMRX0.10
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- ‘Lawyer up’: Democrats take the House, and warn Trump’s family businesses are first in line for subpoenas